162 related articles for article (PubMed ID: 15627019)
1. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer.
Evens AM
Curr Opin Oncol; 2004 Nov; 16(6):576-80. PubMed ID: 15627019
[TBL] [Abstract][Full Text] [Related]
2. Motexafin gadolinium: gadolinium (III) texaphyrin, gadolinium texaphyrin, Gd-Tex, GdT2B2, PCI 0120.
Drugs R D; 2004; 5(1):52-7. PubMed ID: 14725495
[TBL] [Abstract][Full Text] [Related]
3. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
Forouzannia A; Richards GM; Khuntia D; Mehta MP
Expert Rev Anticancer Ther; 2007 Jun; 7(6):785-94. PubMed ID: 17555388
[TBL] [Abstract][Full Text] [Related]
4. Motexafin gadolinium: a novel radiosensitizer for brain tumors.
Francis D; Richards GM; Forouzannia A; Mehta MP; Khuntia D
Expert Opin Pharmacother; 2009 Sep; 10(13):2171-80. PubMed ID: 19640206
[TBL] [Abstract][Full Text] [Related]
5. Motexafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies.
Evens AM; Balasubramanian L; Gordon LI
Curr Treat Options Oncol; 2005 Jul; 6(4):289-96. PubMed ID: 15967082
[TBL] [Abstract][Full Text] [Related]
6. Motexafin gadolinium in the treatment of brain metastases.
Richards GM; Mehta MP
Expert Opin Pharmacother; 2007 Feb; 8(3):351-9. PubMed ID: 17266469
[TBL] [Abstract][Full Text] [Related]
7. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points.
Mehta MP; Shapiro WR; Glantz MJ; Patchell RA; Weitzner MA; Meyers CA; Schultz CJ; Roa WH; Leibenhaut M; Ford J; Curran W; Phan S; Smith JA; Miller RA; Renschler MF
J Clin Oncol; 2002 Aug; 20(16):3445-53. PubMed ID: 12177105
[TBL] [Abstract][Full Text] [Related]
8. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.
Khuntia D; Mehta M
Expert Rev Anticancer Ther; 2004 Dec; 4(6):981-9. PubMed ID: 15606327
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases.
Carde P; Timmerman R; Mehta MP; Koprowski CD; Ford J; Tishler RB; Miles D; Miller RA; Renschler MF
J Clin Oncol; 2001 Apr; 19(7):2074-83. PubMed ID: 11283141
[TBL] [Abstract][Full Text] [Related]
10. Motexafin gadolinium: a possible new radiosensitiser.
Rodrigus P
Expert Opin Investig Drugs; 2003 Jul; 12(7):1205-10. PubMed ID: 12831354
[TBL] [Abstract][Full Text] [Related]
11. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
Meyers CA; Smith JA; Bezjak A; Mehta MP; Liebmann J; Illidge T; Kunkler I; Caudrelier JM; Eisenberg PD; Meerwaldt J; Siemers R; Carrie C; Gaspar LE; Curran W; Phan SC; Miller RA; Renschler MF
J Clin Oncol; 2004 Jan; 22(1):157-65. PubMed ID: 14701778
[TBL] [Abstract][Full Text] [Related]
12. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.
Mehta MP; Shapiro WR; Phan SC; Gervais R; Carrie C; Chabot P; Patchell RA; Glantz MJ; Recht L; Langer C; Sur RK; Roa WH; Mahe MA; Fortin A; Nieder C; Meyers CA; Smith JA; Miller RA; Renschler MF
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1069-76. PubMed ID: 18977094
[TBL] [Abstract][Full Text] [Related]
13. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.
Mehta MP; Rodrigus P; Terhaard CH; Rao A; Suh J; Roa W; Souhami L; Bezjak A; Leibenhaut M; Komaki R; Schultz C; Timmerman R; Curran W; Smith J; Phan SC; Miller RA; Renschler MF
J Clin Oncol; 2003 Jul; 21(13):2529-36. PubMed ID: 12829672
[TBL] [Abstract][Full Text] [Related]
14. Motexafin gadolinium: a novel redox active drug for cancer therapy.
Magda D; Miller RA
Semin Cancer Biol; 2006 Dec; 16(6):466-76. PubMed ID: 17112739
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.
William WN; Zinner RG; Karp DD; Oh YW; Glisson BS; Phan SC; Stewart DJ
J Thorac Oncol; 2007 Aug; 2(8):745-50. PubMed ID: 17762342
[TBL] [Abstract][Full Text] [Related]
16. Motexafin gadolinium injection for the treatment of brain metastases in patients with non-small cell lung cancer.
Thomas SR; Khuntia D
Int J Nanomedicine; 2007; 2(1):79-87. PubMed ID: 17722515
[TBL] [Abstract][Full Text] [Related]
17. The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics.
Olson JJ; Paleologos NA; Gaspar LE; Robinson PD; Morris RE; Ammirati M; Andrews DW; Asher AL; Burri SH; Cobbs CS; Kondziolka D; Linskey ME; Loeffler JS; McDermott M; Mehta MP; Mikkelsen T; Patchell RA; Ryken TC; Kalkanis SN
J Neurooncol; 2010 Jan; 96(1):115-42. PubMed ID: 19957013
[TBL] [Abstract][Full Text] [Related]
18. Radiation sensitization with redox modulators: a promising approach.
Rosenberg A; Knox S
Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):343-54. PubMed ID: 16414370
[TBL] [Abstract][Full Text] [Related]
19. Multimodality management of non-small cell lung cancer patients with brain metastases.
Ricciardi S; de Marinis F
Curr Opin Oncol; 2010 Mar; 22(2):86-93. PubMed ID: 20009927
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
Ramanathan RK; Fakih M; Mani S; Deutsch M; Perez RP; Ritter MA; Eiseman JL; Ivy SP; Trump DL; Belani CP; Parise RA; Potter DM; Egorin MJ
Cancer Chemother Pharmacol; 2006 Apr; 57(4):465-74. PubMed ID: 16133531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
